Adidas looking for New York victory lap in marathon shoe wars

Adidas Running revenue rose 19% in the company’s record third quarter, while Adidas-sponsored runners recorded eight wins at World Marathon Majors this year, strengthening its position against Nike. Adidas has accelerated development of its elite Evo shoe line, with core work taking nine months versus 18–24 months for a typical running shoe. Nike Running has posted six consecutive quarters of double-digit growth, but Nike also forecast a steep full-year revenue drop and announced further restructuring and job cuts.

Analysis

Elite wins can reinforce a performance-led product flywheel for adidas: credibility helps retailers allocate space and gives consumers a reason to trial premium shoes, while athlete testing may shorten the feedback loop on product development. The payoff is not automatic, however. Marathon podiums are a narrow signal; repeat purchases, sell-through, discounting and gross-margin quality are better tests of whether the halo is converting into durable economics.

The category may be expanding rather than simply reallocating share. Rising participation can support adidas, Nike, On and ASICS simultaneously, limiting the inference that adidas’ gains must come directly from Nike. Conversely, Nike’s reported Running growth argues against treating poor marathon results as evidence of a broad franchise collapse. Its restructuring and renewed innovation are credible reversal risks for any relative-value position.

Near term, the NYC result is a noisy, binary publicity catalyst; avoid paying up solely ahead of the race. Over 1–3 months, watch segment growth, channel inventory, full-price sell-through and management commentary for evidence that product credibility is converting to revenue. Over 6–18 months, faster development cycles could improve adidas’ competitiveness, but execution and sustained consumer adoption—not athlete results alone—determine whether that advantage lasts. The contrarian point: the article’s race-win framing may overstate share transfer while understating category growth and Nike’s ongoing product response.

Key Decisions for Investors

• Consider a modest long ADS / short NKE relative-value position only on attractive entry levels, not as a bet on the NYC winner. Thesis: adidas has stronger current performance-shoe momentum; hedge risk is Nike’s Running growth and restructuring-driven recovery. Reassess if adidas Running growth or full-price sell-through weakens, or Nike shows renewed product-led acceleration.
• Do not trade the marathon result in isolation. Treat a win or loss as a short-lived attention catalyst; wait for subsequent channel and earnings evidence before increasing exposure.
• Track adidas and Nike running-category sales, inventory, markdowns and product-level sell-through over the next 1–3 months. These missing indicators determine whether podium credibility is producing profitable consumer demand.
• Keep ONON and Under Armour on the competitive watchlist: participation growth could benefit multiple brands, while persistent adidas gains accompanied by weaker competitor sell-through would make the share-transfer thesis more compelling.